5:10 PM
 | 
Feb 28, 2014
 |  BC Extra  |  Top Story

Abide grants Celgene options

Celgene Corp. (NASDAQ:CELG) paid Abide Therapeutics Inc. (Princeton, N.J.) $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >